TargetBeta
IGF1R
insulin like growth factor 1 receptor · also JTK13, CD221, IGFIR, MGC18216 · CD molecules
6 programs in company-led studies act on IGF1R, from 5 companies: 3 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| teprotumumabrule | Amgen | phase 4 | 181 running | – | NCIt |
| veligrotugrule | Viridian Therapeutics | phase 4 | 71 running | – | NCIt |
| MHB018Arule | Minghui Pharmaceutical | phase 3 | 66 running | – | the studies' text |
| linsitinibrule | Astellas Pharma | phase 3 | 132 running | INSR | NCIt |
| IBI311rule | Innovent Biologics | phase 3 | 51 running | – | the studies' text |
| IBI3031rule | Innovent Biologics | phase 1 | 11 running | TSHR | the studies' text |
Conditions their studies are in
- Graves Ophthalmopathy, 6 programs
- Adrenocortical Carcinoma, 1 program
- Breast Neoplasms, 1 program
- Carcinoma, Hepatocellular, 1 program
- Carcinoma, Non-Small-Cell Lung, 1 program
- Macular Edema, 1 program
- Multiple Myeloma, 1 program
- Neoplasms, 1 program
- Ovarian Neoplasms, 1 program
- Sarcoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026MHB018A · Minghui Pharmaceutical · phase 3 · NCT06989918
- Dec 31, 2026IBI311 · Innovent Biologics · phase 3 · NCT07113262
- Apr 2027veligrotug · Viridian Therapeutics · phase 4 · NCT07832136
- Jun 15, 2027IBI3031 · Innovent Biologics · phase 1 · NCT07622368
- Jun 30, 2028linsitinib · Astellas Pharma · phase 3 · NCT07753603
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.